Top

06-01-2025 | Diabetic Foot | Review Article

Novel antimicrobial strategies for diabetic foot infections: addressing challenges and resistance

Authors: Fahaad Alenazi, Mohd Shahid Khan

Abstract

Aims

This review examines the challenges posed by Diabetic Foot Infections (DFIs), focusing on the impact of neuropathy, peripheral arterial disease, immunopathy, and the polymicrobial nature of these infections. The aim is to explore the factors contributing to antimicrobial resistance and assess the potential of novel antimicrobial treatments and drug delivery systems in improving patient outcomes.

Method

A comprehensive analysis of existing literature on DFIs was conducted, highlighting the multifactorial pathogenesis and polymicrobial composition of these infections. The review delves into the rise of antimicrobial resistance due to the overuse of antimicrobials, biofilm formation, and microbial genetic adaptability. Additionally, it considers glycemic control, patient adherence, and recurrence rates as contributing factors to treatment failure. Emerging therapies, including new antimicrobial classes and innovative drug delivery systems, were evaluated for their potential efficacy.

Results

DFIs present unique treatment challenges, with high rates of antimicrobial resistance and poor response to standard therapies. Biofilm formation and the genetic adaptability of pathogens worsen resistance, complicating treatment. Current antimicrobial therapies are further hindered by poor glycemic control and patient adherence, leading to recurrent infections. Novel antimicrobial classes and innovative delivery systems show promise in addressing these challenges by offering more targeted, effective treatments. These new approaches aim to reduce resistance and improve treatment outcomes.

Conclusion

DFIs remain a clinical challenge due to their multifactorial nature and antimicrobial resistance. The development of novel antimicrobials and drug delivery systems is crucial to improving patient outcomes and combating resistance. Future research should focus on enhancing treatment efficacy, reducing resistance, and addressing patient adherence to reduce the burden of DFIs.

Available only for authorised users

Waibel FWA, Uçkay I, Soldevila-Boixader L et al (2023) Current knowledge of morbidities and direct costs related to diabetic foot disorders: a literature review. Front Endocrinol (Lausanne) 14:1323315. https://doi.org/10.3389/fendo.2023.1323315CrossRefPubMed

Ramirez-Acuña JM, Cardenas-Cadena SA, Marquez-Salas PA et al (2019) Diabetic Foot Ulcers: current advances in Antimicrobial therapies and emerging treatments. Antibiot (Basel) 8:193. https://doi.org/10.3390/antibiotics8040193CrossRef

Ali Alghamdi B, Al-Johani I, Al-Shamrani JM et al (2023) Antimicrobial resistance in methicillin-resistant staphylococcus aureus. Saudi J Biol Sci 30:103604. https://doi.org/10.1016/j.sjbs.2023.103604CrossRefPubMedPubMedCentral

Breijyeh Z, Karaman R (2023) Design and synthesis of Novel Antimicrobial agents. Antibiot (Basel) 12:628. https://doi.org/10.3390/antibiotics12030628CrossRef

Jo SJ, Kwon J, Kim SG, Lee S-J (2023) The Biotechnological Application of bacteriophages: what to do and where to go in the Middle of the post-antibiotic era. Microorganisms 11:2311. https://doi.org/10.3390/microorganisms11092311CrossRefPubMedPubMedCentral

Armstrong DG, Boulton AJM, Bus SA (2017) Diabetic Foot Ulcers and their recurrence. N Engl J Med 376:2367–2375. https://doi.org/10.1056/NEJMra1615439CrossRefPubMed

Sadeghpour Heravi F, Zakrzewski M, Vickery K et al (2019) Bacterial Diversity of Diabetic Foot Ulcers: Current Status and Future Prospectives. J Clin Med 8:1935. https://doi.org/10.3390/jcm8111935

Speziale P, Pietrocola G, Foster TJ, Geoghegan JA (2014) Protein-based biofilm matrices in Staphylococci. Front Cell Infect Microbiol 4:171. https://doi.org/10.3389/fcimb.2014.00171CrossRefPubMedPubMedCentral

Tuon FF, Suss PH, Telles JP et al (2023) Antimicrobial Treatment of Staphylococcus aureus Biofilms. Antibiot (Basel) 12:87. https://doi.org/10.3390/antibiotics12010087CrossRef

10.

Tong SYC, Davis JS, Eichenberger E et al (2015) Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28:603–661. https://doi.org/10.1128/CMR.00134-14CrossRefPubMedPubMedCentral

11.

Brouwer S, Rivera-Hernandez T, Curren BF et al (2023) Pathogenesis, epidemiology and control of Group A Streptococcus infection. Nat Rev Microbiol 21:431–447. https://doi.org/10.1038/s41579-023-00865-7CrossRefPubMedPubMedCentral

12.

Starr CR, Engleberg NC (2006) Role of hyaluronidase in subcutaneous spread and growth of group a streptococcus. Infect Immun 74:40–48. https://doi.org/10.1128/IAI.74.1.40-48.2006CrossRefPubMed

13.

Spaulding AR, Salgado-Pabón W, Kohler PL et al (2013) Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev 26:422–447. https://doi.org/10.1128/CMR.00104-12CrossRefPubMedPubMedCentral

14.

Shumba P, Mairpady Shambat S, Siemens N (2019) The role of Streptococcal and Staphylococcal exotoxins and proteases in Human Necrotizing Soft tissue infections. Toxins (Basel) 11:332. https://doi.org/10.3390/toxins11060332CrossRefPubMed

15.

Syed S, Viazmina L, Mager R et al (2020) Streptococci and the complement system: interplay during infection, inflammation and autoimmunity. FEBS Lett 594:2570–2585. https://doi.org/10.1002/1873-3468.13872CrossRefPubMed

16.

Hazare C, Bhagwat P, Singh S, Pillai S (2024) Diverse origins of fibrinolytic enzymes: a comprehensive review. Heliyon 10:e26668. https://doi.org/10.1016/j.heliyon.2024.e26668CrossRefPubMedPubMedCentral

17.

Peng Q, Tang X, Dong W et al (2022) A review of Biofilm formation of Staphylococcus aureus and its regulation mechanism. Antibiot (Basel) 12:12. https://doi.org/10.3390/antibiotics12010012CrossRef

18.

Tenaillon O, Skurnik D, Picard B, Denamur E (2010) The population genetics of commensal Escherichia coli. Nat Rev Microbiol 8:207–217. https://doi.org/10.1038/nrmicro2298CrossRefPubMed

19.

Giurato L, Meloni M, Izzo V, Uccioli L (2017) Osteomyelitis in diabetic foot: a comprehensive overview. World J Diabetes 8:135–142. https://doi.org/10.4239/wjd.v8.i4.135CrossRefPubMedPubMedCentral

20.

Huang X, Li X, An H et al (2022) Capsule type defines the capability of Klebsiella pneumoniae in evading Kupffer cell capture in the liver. PLoS Pathog 18:e1010693. https://doi.org/10.1371/journal.ppat.1010693CrossRefPubMedPubMedCentral

21.

Sabença C, Costa E, Sousa S et al (2023) Evaluation of the ability to Form Biofilms in KPC-Producing and ESBL-Producing Klebsiella pneumoniae isolated from clinical samples. Antibiot (Basel) 12:1143. https://doi.org/10.3390/antibiotics12071143CrossRef

22.

Schaffer JN, Pearson MM (2015) Proteus mirabilis and urinary tract infections. https://doi.org/10.1128/microbiolspec.UTI-0017-2013. Microbiol Spectr 3:

23.

Wasfi R, Hamed SM, Amer MA, Fahmy LI (2020) Proteus mirabilis Biofilm: development and therapeutic strategies. Front Cell Infect Microbiol 10:414. https://doi.org/10.3389/fcimb.2020.00414CrossRefPubMedPubMedCentral

24.

Uçkay I, Lebowitz D, Kressmann B et al (2022) Pseudomonal Diabetic Foot infections: Vive La Différence? Mayo Clin Proc Innov Qual Outcomes 6:250–256. https://doi.org/10.1016/j.mayocpiqo.2022.04.005CrossRefPubMedPubMedCentral

25.

Qin S, Xiao W, Zhou C et al (2022) Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Sig Transduct Target Ther 7:199. https://doi.org/10.1038/s41392-022-01056-1CrossRef

26.

Zhang P, Lu J, Jing Y et al (2017) Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis †. Ann Med 49:106–116. https://doi.org/10.1080/07853890.2016.1231932CrossRefPubMed

27.

Boulton AJM, Armstrong DG, Albert SF et al (2008) Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 31:1679–1685. https://doi.org/10.2337/dc08-9021CrossRefPubMedPubMedCentral

28.

Monteiro-Soares M, Boyko EJ, Jeffcoate W et al (2020) Diabetic foot ulcer classifications: a critical review. Diabetes Metab Res Rev 36 Suppl 1e3272. https://doi.org/10.1002/dmrr.3272

29.

Lin J, Song H, Liang M et al (2022) Advances in the study of OSA and diabetic foot. Diabetol Metab Syndr 14:70. https://doi.org/10.1186/s13098-022-00842-9CrossRefPubMedPubMedCentral

30.

Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570–2581. https://doi.org/10.1001/jama.287.19.2570CrossRefPubMed

31.

Hingorani A, LaMuraglia GM, Henke P et al (2016) The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg 63:3S–21S. https://doi.org/10.1016/j.jvs.2015.10.003CrossRefPubMed

32.

Conte MS, Bradbury AW, Kolh P et al (2019) Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg 69. https://doi.org/10.1016/j.jvs.2019.02.016.:3S-125S.e40

33.

Game FL, Apelqvist J, Attinger C et al (2016) Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review. Diabetes Metab Res Rev 32(Suppl 1):154–168. https://doi.org/10.1002/dmrr.2707CrossRefPubMed

34.

Ministrini S, Andreozzi F, Montecucco F et al (2021) Neutrophil degranulation biomarkers characterize restrictive echocardiographic pattern with diastolic dysfunction in patients with diabetes. Eur J Clin Invest 51:e13640. https://doi.org/10.1111/eci.13640CrossRefPubMedPubMedCentral

35.

Aitcheson SM, Frentiu FD, Hurn SE et al (2021) Skin Wound Healing: normal macrophage function and macrophage dysfunction in Diabetic wounds. Molecules 26:4917. https://doi.org/10.3390/molecules26164917CrossRefPubMedPubMedCentral

36.

Hull CM, Peakman M, Tree TIM (2017) Regulatory T cell dysfunction in type 1 diabetes: what’s broken and how can we fix it? Diabetologia 60:1839–1850. https://doi.org/10.1007/s00125-017-4377-1CrossRefPubMedPubMedCentral

37.

Deng H, Li B, Shen Q et al (2023) Mechanisms of diabetic foot ulceration: a review. J Diabetes 15:299–312. https://doi.org/10.1111/1753-0407.13372CrossRefPubMedPubMedCentral

38.

Kaabi YA (2022) Potential roles of anti-inflammatory plant-derived bioactive compounds targeting inflammation in Microvascular complications of Diabetes. Molecules 27:7352. https://doi.org/10.3390/molecules27217352CrossRefPubMedPubMedCentral

39.

Rajab AAH, Hegazy WAH (2023) What’s old is new again: insights into diabetic foot microbiome. World J Diabetes 14:680–704. https://doi.org/10.4239/wjd.v14.i6.680CrossRefPubMedPubMedCentral

40.

Darwitz BP, Genito CJ, Thurlow LR (2024) Triple threat: how diabetes results in worsened bacterial infections. Infect Immun. https://doi.org/10.1128/iai.00509-23. e00509-23CrossRefPubMedPubMedCentral

41.

Pouget C, Dunyach-Remy C, Pantel A et al (2021) Alternative approaches for the Management of Diabetic Foot Ulcers. Front Microbiol 12:747618. https://doi.org/10.3389/fmicb.2021.747618CrossRefPubMedPubMedCentral

42.

Giurato L, Meloni M, Izzo V, Uccioli L (2017) Osteomyelitis in diabetic foot: a comprehensive overview. WJD 8:135. https://doi.org/10.4239/wjd.v8.i4.135CrossRefPubMedPubMedCentral

43.

Soyoye DO, Abiodun OO, Ikem RT et al (2021) Diabetes and peripheral artery disease: a review. WJD 12:827–838. https://doi.org/10.4239/wjd.v12.i6.827CrossRefPubMedPubMedCentral

44.

Boschetti G, Sgarabotto D, Meloni M et al (2021) Antimicrobial resistance patterns in Diabetic Foot infections, an epidemiological study in Northeastern Italy. Antibiotics 10:1241. https://doi.org/10.3390/antibiotics10101241CrossRefPubMedPubMedCentral

45.

Thiruvoipati T (2015) Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. WJD 6:961. https://doi.org/10.4239/wjd.v6.i7.961CrossRefPubMedPubMedCentral

46.

Bowler PG, Duerden BI, Armstrong DG (2001) Wound Microbiology and Associated approaches to Wound Management. Clin Microbiol Rev 14:244–269. https://doi.org/10.1128/CMR.14.2.244-269.2001CrossRefPubMedPubMedCentral

47.

Boulton A, Armstrong D, Krisner R et al (2018) Diagnosis and management of Diabetic Foot complications. Compendia 2018:1–20. https://doi.org/10.2337/db20182-1CrossRef

48.

Aslangul E, M’Bemba J, Caillat-Vigneron N et al (2013) Diagnosing Diabetic Foot osteomyelitis in patients without signs of Soft tissue infection by coupling hybrid 67Ga SPECT/CT with Bedside Percutaneous Bone puncture. Diabetes Care 36:2203–2210. https://doi.org/10.2337/dc12-2108CrossRefPubMedPubMedCentral

49.

Meloni M, Bellizzi E, Andreadi A et al (2024) Diabetic Foot osteomyelitis in patients with and without peripheral arterial disease: two different diseases? Int J Low Extrem Wounds 15347346241264383. https://doi.org/10.1177/15347346241264383

50.

Dobaria DG, Cohen HL (2023) Osteomyelitis Imaging. StatPearls [Internet]. StatPearls Publishing

51.

Panteli M, Giannoudis PV (2016) Chronic osteomyelitis: what the surgeon needs to know. EFORT Open Reviews 1:128–135. https://doi.org/10.1302/2058-5241.1.000017CrossRefPubMedPubMedCentral

52.

Lipsky BA, Senneville É, Abbas ZG et al (2020) Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 36(Suppl 1):e3280. https://doi.org/10.1002/dmrr.3280CrossRefPubMed

53.

Nelson SB (2009) Management of diabetic foot infections in an era of increasing microbial resistance. Curr Infect Dis Rep 11:375–382. https://doi.org/10.1007/s11908-009-0053-zCrossRefPubMed

54.

Quinn JV, Wells GA (1998) An Assessment of clinical wound evaluation scales. Acad Emerg Med 5:583–586. https://doi.org/10.1111/j.1553-2712.1998.tb02465.xCrossRefPubMed

55.

Game FL, Hinchliffe RJ, Apelqvist J et al (2012) A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metabolism Res 28:119–141. https://doi.org/10.1002/dmrr.2246CrossRef

56.

Lipsky BA, Berendt AR, Cornia PB et al (2012) 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 54:e132–173. https://doi.org/10.1093/cid/cis346CrossRefPubMed

57.

Guidelines (2023) update In: IWGDF Guidelines. https://iwgdfguidelines.org/guidelines-2023/. Accessed 23 Nov 2024

58.

Baig MS, Banu A, Zehravi M et al (2022) An overview of Diabetic Foot Ulcers and Associated problems with special emphasis on treatments with antimicrobials. Life (Basel) 12:1054. https://doi.org/10.3390/life12071054CrossRefPubMed

59.

Zapata D, Higgs J, Wittholt H et al (2022) Nanotechnology in the diagnosis and treatment of Osteomyelitis. Pharmaceutics 14:1563. https://doi.org/10.3390/pharmaceutics14081563CrossRefPubMedPubMedCentral

60.

van Netten JJ, Raspovic A, Lavery LA et al (2020) Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review. Diabetes Metab Res Rev 36(Suppl 1):e3270. https://doi.org/10.1002/dmrr.3270CrossRefPubMed

61.

Lipsky BA (2016) Diabetic foot infections: current treatment and delaying the post-antibiotic era. Diabetes Metab Res Rev 32(Suppl 1):246–253. https://doi.org/10.1002/dmrr.2739CrossRefPubMed

62.

Dardari D, Franc S, Charpentier G et al (2023) Hospital stays and costs of telemedical monitoring versus standard follow-up for diabetic foot ulcer: an open-label randomised controlled study. Lancet Reg Health Eur 32:100686. https://doi.org/10.1016/j.lanepe.2023.100686CrossRefPubMedPubMedCentral

63.

James GA, Swogger E, Wolcott R et al (2008) Biofilms in chronic wounds. Wound Repair Regen 16:37–44. https://doi.org/10.1111/j.1524-475X.2007.00321.xCrossRefPubMed

64.

Afonso AC, Oliveira D, Saavedra MJ et al (2021) Biofilms in Diabetic Foot Ulcers: impact, risk factors and control strategies. Int J Mol Sci 22:8278. https://doi.org/10.3390/ijms22158278CrossRefPubMedPubMedCentral

65.

Kosiyaporn H, Chanvatik S, Issaramalai T et al (2020) Surveys of knowledge and awareness of antibiotic use and antimicrobial resistance in general population: a systematic review. PLoS ONE 15:e0227973. https://doi.org/10.1371/journal.pone.0227973CrossRefPubMedPubMedCentral

66.

Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74:417–433. https://doi.org/10.1128/MMBR.00016-10CrossRefPubMedPubMedCentral

67.

Paul M, Carmeli Y, Durante-Mangoni E et al (2014) Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69:2305–2309. https://doi.org/10.1093/jac/dku168CrossRefPubMed

68.

Yan X, Song J-F, Zhang L, Li X (2022) Analysis of risk factors for multidrug-resistant organisms in diabetic foot infection. BMC Endocr Disord 22:46. https://doi.org/10.1186/s12902-022-00957-0CrossRefPubMedPubMedCentral

69.

Lewis K (2020) The Science of Antibiotic Discovery. Cell 181:29–45. https://doi.org/10.1016/j.cell.2020.02.056CrossRefPubMed

70.

Dellit TH, Owens RC, McGowan JE et al (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159–177. https://doi.org/10.1086/510393CrossRefPubMed

71.

Gerace E, Mancuso G, Midiri A et al (2022) Recent advances in the Use of Molecular methods for the diagnosis of bacterial infections. Pathogens 11:663. https://doi.org/10.3390/pathogens11060663CrossRefPubMedPubMedCentral

72.

Kaprou GD, Bergšpica I, Alexa EA et al (2021) Rapid Methods for Antimicrobial Resistance Diagnostics. Antibiot (Basel) 10:209. https://doi.org/10.3390/antibiotics10020209CrossRef

73.

Tamma PD, Cosgrove SE, Maragakis LL (2012) Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 25:450–470. https://doi.org/10.1128/CMR.05041-11CrossRefPubMedPubMedCentral

74.

Burdette SD, Trotman R (2015) Tedizolid: the First once-Daily Oxazolidinone Class Antibiotic. Clin Infect Dis 61:1315–1321. https://doi.org/10.1093/cid/civ501CrossRefPubMed

75.

Hashemian SMR, Farhadi T, Ganjparvar M (2018) Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther 12:1759–1767. https://doi.org/10.2147/DDDT.S164515CrossRefPubMedPubMedCentral

76.

McGuinness WA, Malachowa N, DeLeo FR (2017) Vancomycin Resistance in Staphylococcus aureus. Yale J Biol Med 90:269–281PubMedPubMedCentral

77.

Zhang H, Zhou W, Wang J, Cai Y (2021) Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis. J Glob Antimicrob Resist 25:380–389. https://doi.org/10.1016/j.jgar.2021.04.013CrossRefPubMed

78.

Sader HS, Flamm RK, Streit JM et al (2015) Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program. Antimicrob Agents Chemother 59:2458–2461. https://doi.org/10.1128/AAC.04614-14CrossRefPubMedPubMedCentral

79.

Jia P, Zhu Y, Zhang H et al (2022) In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program. BMC Microbiol 22:234. https://doi.org/10.1186/s12866-022-02644-5CrossRefPubMedPubMedCentral

80.

Steenbergen JN, Alder J, Thorne GM, Tally FP (2005) Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55:283–288. https://doi.org/10.1093/jac/dkh546CrossRefPubMed

81.

Beiras-Fernandez A, Vogt F, Sodian R, Weis F (2010) Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens. Infect Drug Resist 3:95–101. https://doi.org/10.2147/IDR.S6961CrossRefPubMedPubMedCentral

82.

Lan S-H, Lin W-T, Chang S-P et al (2019) Tedizolid Versus Linezolid for the treatment of Acute bacterial skin and skin structure infection: a systematic review and Meta-analysis. Antibiot (Basel) 8137. https://doi.org/10.3390/antibiotics8030137

83.

Siciliano V, Sangiorgi F, Del Vecchio P et al (2024) New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides. Pathogens 13:189. https://doi.org/10.3390/pathogens13030189CrossRefPubMedPubMedCentral

84.

Corey GR, Wilcox MH, Talbot GH et al (2010) CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65(Suppl 4):iv41–51. https://doi.org/10.1093/jac/dkq254CrossRefPubMed

85.

Zia Q, Azhar A, Amjad Kamal M et al (2016) Super aggregated form of amphotericin B: a novel way to increase its therapeutic index. CPD 22:792–803. https://doi.org/10.2174/1381612822666151209151719CrossRef

86.

Ghosh R, De M (2023) Liposome-based antibacterial delivery: an Emergent Approach to combat bacterial infections. ACS Omega 8:35442–35451. https://doi.org/10.1021/acsomega.3c04893CrossRefPubMedPubMedCentral

87.

Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polym (Basel) 3:1377–1397. https://doi.org/10.3390/polym3031377CrossRef

88.

Hoare TR, Kohane DS (2008) Hydrogels in drug delivery: Progress and challenges. Polymer 49:1993–2007. https://doi.org/10.1016/j.polymer.2008.01.027CrossRef

89.

Kim Y-C, Park J-H, Prausnitz MR (2012) Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 64:1547–1568. https://doi.org/10.1016/j.addr.2012.04.005CrossRefPubMedPubMedCentral

90.

Rai MK, Deshmukh SD, Ingle AP, Gade AK (2012) Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. J Appl Microbiol 112:841–852. https://doi.org/10.1111/j.1365-2672.2012.05253.xCrossRefPubMed

91.

Shubayev VI, Pisanic TR, Jin S (2009) Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 61:467–477. https://doi.org/10.1016/j.addr.2009.03.007CrossRefPubMedPubMedCentral

92.

Gupta Y, Ghrera AS (2021) Recent advances in gold nanoparticle-based lateral flow immunoassay for the detection of bacterial infection. Arch Microbiol 203:3767–3784. https://doi.org/10.1007/s00203-021-02357-9CrossRefPubMed

93.

Pham SH, Choi Y, Choi J (2020) Stimuli-Responsive nanomaterials for application in Antitumor Therapy and Drug Delivery. Pharmaceutics 12:630. https://doi.org/10.3390/pharmaceutics12070630CrossRefPubMedPubMedCentral

94.

Xiang Z, Liu M, Song J (2021) Stimuli-Responsive Polymeric nanosystems for Controlled Drug Delivery. Appl Sci 11:9541. https://doi.org/10.3390/app11209541CrossRef

95.

Ku Y-H, Yu W-L (2021) Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria? Infect Genet Evol 88:104707. https://doi.org/10.1016/j.meegid.2021.104707CrossRefPubMed

96.

Almangour TA, Ghonem L, Alassiri D et al (2023) Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the treatment of infections caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study. Antimicrob Agents Chemother 67:e0040523. https://doi.org/10.1128/aac.00405-23CrossRefPubMed

97.

Butler MS, Hansford KA, Blaskovich MAT et al (2014) Glycopeptide antibiotics: back to the future. J Antibiot 67:631–644. https://doi.org/10.1038/ja.2014.111CrossRef

98.

Lipsky BA, Stoutenburgh U (2005) Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with Vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 55:240–245. https://doi.org/10.1093/jac/dkh531CrossRefPubMed

99.

Bassetti M, Castaldo N, Carnelutti A et al (2019) Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy. Core Evid 14:31–40. https://doi.org/10.2147/CE.S187499CrossRefPubMedPubMedCentral

100.

Mougakou E, Mastrogianni E, Kyziroglou M, Tziomalos K (2023) The role of Novel antibiotics in the Management of Diabetic Foot infection. Diabetes Ther 14:251–263. https://doi.org/10.1007/s13300-022-01357-2CrossRefPubMed

101.

Kaye KS, Naas T, Pogue JM, Rossolini GM (2023) Cefiderocol, a Siderophore Cephalosporin, as a treatment option for infections caused by Carbapenem-Resistant Enterobacterales. Infect Dis Ther 12:777–806. https://doi.org/10.1007/s40121-023-00773-6CrossRefPubMedPubMedCentral

102.

Sacco E, Cortes M, Josseaume N et al (2015) Mutation landscape of acquired cross-resistance to glycopeptide and β-lactam antibiotics in Enterococcus faecium. Antimicrob Agents Chemother 59:5306–5315. https://doi.org/10.1128/AAC.00634-15CrossRefPubMedPubMedCentral

103.

Lin DM, Koskella B, Lin HC (2017) Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 8:162–173. https://doi.org/10.4292/wjgpt.v8.i3.162CrossRefPubMedPubMedCentral

104.

Mangas EL, Rubio A, Álvarez-Marín R et al (2019) Pangenome of Acinetobacter baumannii uncovers two groups of genomes, one of them with genes involved in CRISPR/Cas defence systems associated with the absence of plasmids and exclusive genes for biofilm formation. Microb Genom 5:e000309. https://doi.org/10.1099/mgen.0.000309CrossRefPubMedPubMedCentral

105.

Olsen I (2015) Biofilm-specific antibiotic tolerance and resistance. Eur J Clin Microbiol Infect Dis 34:877–886. https://doi.org/10.1007/s10096-015-2323-zCrossRefPubMed

106.

Velikova TV, Kabakchieva PP, Assyov YS, Georgiev TА (2021) Targeting Inflammatory cytokines to improve type 2 Diabetes Control. Biomed Res Int 2021:7297419. https://doi.org/10.1155/2021/7297419CrossRefPubMedPubMedCentral

107.

Nirenjen S, Narayanan J, Tamilanban T et al (2023) Exploring the contribution of pro-inflammatory cytokines to impaired wound healing in diabetes. Front Immunol 14:1216321. https://doi.org/10.3389/fimmu.2023.1216321CrossRefPubMedPubMedCentral

108.

Qadri H, Shah AH, Alkhanani M et al (2023) Immunotherapies against human bacterial and fungal infectious diseases: a review. Front Med (Lausanne) 10:1135541. https://doi.org/10.3389/fmed.2023.1135541CrossRefPubMed

109.

Panwar RB, Sequeira RP, Clarke TB (2021) Microbiota-mediated protection against antibiotic-resistant pathogens. Genes Immun 22:255–267. https://doi.org/10.1038/s41435-021-00129-5CrossRefPubMedPubMedCentral

110.

Shukla R, Lavore F, Maity S et al (2022) Teixobactin kills bacteria by a two-pronged attack on the cell envelope. Nature 608:390–396. https://doi.org/10.1038/s41586-022-05019-yCrossRefPubMedPubMedCentral

111.

Kumar L, Bisen M, Harjai K et al (2023) Advances in nanotechnology for Biofilm Inhibition. ACS Omega 8:21391–21409. https://doi.org/10.1021/acsomega.3c02239CrossRefPubMedPubMedCentral

112.

Dhanda G, Acharya Y, Haldar J (2023) Antibiotic adjuvants: a Versatile Approach to Combat Antibiotic Resistance. ACS Omega 8:10757–10783. https://doi.org/10.1021/acsomega.3c00312CrossRefPubMedPubMedCentral

113.

Brives C, Pourraz J (2020) Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures. Palgrave Commun 6:100. https://doi.org/10.1057/s41599-020-0478-4CrossRef

114.

Mayorga-Ramos A, Zúñiga-Miranda J, Carrera-Pacheco SE et al (2023) CRISPR-Cas-based antimicrobials: design, challenges, and bacterial mechanisms of resistance. ACS Infect Dis 9:1283–1302. https://doi.org/10.1021/acsinfecdis.2c00649CrossRefPubMedPubMedCentral

Title: Novel antimicrobial strategies for diabetic foot infections: addressing challenges and resistance
Authors: Fahaad Alenazi
Mohd Shahid Khan
Publication date: 06-01-2025
Publisher: Springer Milan
Keywords: Diabetic Foot
Peripheral Arterial Disease
Peripheral Arterial Disease
Published in: Acta Diabetologica
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-024-02438-3

Keynote webinar | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Abstract

Aims

Method

Results

Conclusion

Please log in to get access to this content

Keynote webinar | Spotlight on menopause

Keynote webinar | Spotlight on adolescent vaping

Keynote webinar | Spotlight on modern management of frailty

A quick guide to ECGs

At a glance: The STEP trials